Your browser doesn't support javascript.
loading
Altered peptide ligands revisited: vaccine design through chemically modified HLA-A2-restricted T cell epitopes.
Hoppes, Rieuwert; Oostvogels, Rimke; Luimstra, Jolien J; Wals, Kim; Toebes, Mireille; Bies, Laura; Ekkebus, Reggy; Rijal, Pramila; Celie, Patrick H N; Huang, Julie H; Emmelot, Maarten E; Spaapen, Robbert M; Lokhorst, Henk; Schumacher, Ton N M; Mutis, Tuna; Rodenko, Boris; Ovaa, Huib.
Afiliação
  • Hoppes R; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Oostvogels R; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands Department of Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands;
  • Luimstra JJ; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Wals K; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Toebes M; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Bies L; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Ekkebus R; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Rijal P; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Celie PH; Division of Biochemistry, The Netherlands Cancer Institute Protein Facility, 1066 CX Amsterdam, the Netherlands; and.
  • Huang JH; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
  • Emmelot ME; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
  • Spaapen RM; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Lokhorst H; Department of Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands;
  • Schumacher TN; Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
  • Mutis T; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
  • Rodenko B; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, United Kingdom b.rodenko@nki.nl h.ovaa@nki.nl.
  • Ovaa H; Division of Cell Biology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands;
J Immunol ; 193(10): 4803-13, 2014 Nov 15.
Article em En | MEDLINE | ID: mdl-25311806
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Antígeno HLA-A2 / Vacinas Anticâncer / Antígenos de Neoplasias / Neoplasias Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Antígeno HLA-A2 / Vacinas Anticâncer / Antígenos de Neoplasias / Neoplasias Idioma: En Ano de publicação: 2014 Tipo de documento: Article